Research programme: extracorporeal antibody therapies - Premier Biomedical

Drug Profile

Research programme: extracorporeal antibody therapies - Premier Biomedical

Alternative Names: Sequential dialysis therapy - Premier Biomedical

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Premier Biomedical
  • Developer Premier Biomedical; University of Texas at El Paso; William Beaumont Army Medical Center
  • Class Monoclonal antibodies
  • Mechanism of Action Cytokine inhibitors; Glutamate modulators; Immunomodulators; Neurotransmitter inhibitors; Neurotransmitter modulators; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer metastases
  • Research Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Cockayne syndrome; Neurofibromatoses
  • No development reported Major depressive disorder; Retinitis pigmentosa

Most Recent Events

  • 09 May 2017 Early research development is ongoing for Alzheimer's disease and Brain injuries in USA
  • 09 May 2017 Premier Biomedical is seeking partners to develop sequential dialysis technique for development of extracorporeal antibody therapies as of 18 May 2017.
  • 09 May 2017 Premier Biomedical has patent protection for extracorporeal therapy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top